Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
Viral bronchiolitis is a common clinical syndrome affecting infants and young children. Concern about its associated morbidity and cost has led to a large body of research that has been summarised in systematic reviews and integrated into clinical practice guidelines in several countries. The evidence and guideline recommendations consistently support a clinical diagnosis with the limited role for diagnostic testing for children presenting with the typical clinical syndrome of viral upper respiratory infection progressing to the lower respiratory tract. Management is largely supportive, focusing on maintaining oxygenation and hydration of the patient. Evidence suggests no benefit from bronchodilator or corticosteroid use in infants with a first episode of bronchiolitis. Evidence for other treatments such as hypertonic saline is evolving but not clearly defined yet. For infants with severe disease, the insufficient available data suggest a role for high-flow nasal cannula and continuous positive airway pressure use in a monitored setting to prevent respiratory failure.

Introduction

Acute bronchiolitis, a viral infection of the lower respiratory tract, is one of the most substantial health burdens for infants and young children worldwide. Respiratory syncytial virus is the most prevalent viral cause of bronchiolitis in infants. Estimates suggest that about 34 million new cases of lower respiratory infection due to respiratory syncytial virus occur globally in about 34 million new cases of lower respiratory infection due to respiratory syncytial virus occur globally in children younger than 5 years, with 3·4 million admissions to hospitals and about 199 000 deaths per year, predominantly in the developing world. In developed countries such as the USA, bronchiolitis is the most common reason for admission to hospital in the first 12 months of life, accounting for approximately 100 000 infant admissions annually. Although admissions to hospital have declined from 2000 to 2010, emergency department visits have increased, in addition to increased use of mechanical ventilation and hospital charges.

The clinical management remains challenging despite the frequency, global reach, economic cost, and morbidity and mortality associated with bronchiolitis. Several treatment strategies (including bronchodilators and corticosteroids) showed no effect in pooled meta-analyses, making supportive care the hallmark of current therapy. In this Seminar, we aim to summarise the current evidence for the epidemiology, pathophysiology, diagnostic approach, and management of acute viral bronchiolitis.

Epidemiology

Bronchiolitis is a seasonal infection, with the season typically beginning in late October in the temperate northern hemisphere, peaking in January or February, and ending in April. Globally, independent of region, respiratory syncytial virus infection peaks consistently during annual or biannual epidemics. Although the peak and duration of these epidemics vary worldwide, they are consistent year-to-year within a country. Some data suggest that climate might also be associated with prevalence of respiratory syncytial virus infection, with global surveillance suggesting that infection peaks during wet months in areas with high precipitation and during cooler months in hot regions. Indoor crowding in population-dense areas during rainy seasons or cooler months might be one factor that facilitates viral transmission. Additionally, weather-related factors, such as inhalation of cold and dry air that might impair ciliary function, the airway mucosa, and inhibitors of temperature-dependent antiviral responses, might influence both disease transmission and severity. Altitude, climate, and meteorological conditions (such as wind speed and dew point) have been shown to have a modest association with bronchiolitis. Furthermore, air pollutants, such as ozone and traffic pollutants, have been associated with exacerbations of respiratory infections in children younger than 5 years. Environmental tobacco smoke has been associated with increased risk for respiratory syncytial virus-attributable admission to hospital and disease severity in those admitted.

As with other respiratory viral infections, the risk of severe respiratory syncytial virus bronchiolitis might be greater in boys than in girls. This difference might be due to differences in lung and airway development, and by genetic factors.
**Pathophysiology**

Bronchiolitis is characterised by extensive inflammation and oedema of the airways, increased mucus production, and necrosis of airway epithelial cells. Respiratory syncytial virus binds to epithelial cells and replicates, resulting in epithelial necrosis and ciliary destruction. The cell destruction triggers an inflammatory response with proliferation of polymorphonuclear cells and lymphocytes. The submucosa and adventitial tissues become oedematous with increased mucus secretion. Plugs composed of cellular debris and mucus form in the bronchiole lumens leading to bronchiolar obstruction, air trapping, and different degrees of lobar collapse.

**Microbiology**

Molecular testing has led to an improved understanding of the viruses associated with bronchiolitis. Respiratory syncytial virus remains the most commonly identified virus, detected in 41–83% of patients. Other viruses associated with bronchiolitis include rhinovirus, metapneumovirus, coronavirus, human bocavirus, influenza virus, adenovirus, and parainfluenza virus. Studies have investigated whether severity of illness, as measured by need for hospital admission, length of hospital stay, intensive care unit admission, repeated emergency department visits, and apnoea, is associated with specific viral infections or co-infections, but the evidence is conflicting. Data from some studies have shown that in infections involving a single virus, respiratory syncytial virus is associated with a more severe course compared with other viruses. Up to 30% of children with bronchiolitis are found to have co-infections with two other viruses, with the combination of respiratory syncytial virus and rhinovirus being the most commonly reported. Some evidence suggests that co-infection in bronchiolitis, particularly respiratory syncytial virus in combination with rhinovirus or metapneumovirus, could be associated with a more severe disease course compared with infection by a single virus. However, other studies do not confirm this association.

Furthermore, although use of nucleic acid amplification tests has greatly improved our ability to detect viruses present in respiratory infections, studies using these technologies have also found at least one respiratory virus in up to 30% of children younger than 6 years with no respiratory symptoms. These viruses might be detected because of asymptomatic colonisation, incubation before clinical infection, or prolonged viral shedding post-infection. The conflicting evidence and high prevalence of respiratory viruses in asymptomatic children suggest no indication at this time that management should vary based on presumed viral cause and presence, or absence of viral co-infections.

**Clinical presentation and differential diagnosis**

The diagnosis of bronchiolitis is clinical and thus requires a clinician to recognise signs and symptoms of viral lower respiratory tract infection in young children. Peak incidence occurs between 3 months and 6 months of age. Since the early clinical definition by Court, and as noted in recent practice guidelines, the most specific definition is in infants. Although the same physiology can occur in toddlers older than 12 months, many clinical trials have excluded these children or have included them as a small subgroup of patients. Bronchiolitis in toddlers can overlap with other conditions such as viral-induced wheezing and asthma, and application of evidence from trials predominantly assessing infants might not be appropriate. Further efforts to focus the definition might assist efforts to standardise care.

The classic clinical presentation of bronchiolitis starts with symptoms of a viral upper respiratory infection, such as nasal discharge, that progress to the lower respiratory tract over several days (figure 1). Timing of symptom progression can vary, and young infants can present with apnoea. Lower respiratory tract symptoms of bronchiolitis include persistent cough, tachypnoea, and increased work of breathing, as shown by intercostal or supracaclival retractions, use of abdominal muscles, grunting, or nasal flaring. Auscultatory findings include crackles and wheeze. A hallmark characteristic of
bronchiolitis is the minute-to-minute variation in clinical findings, as mucus and debris in the airways are cleared by coughing or as the child’s state changes from sleep to agitation. This variation can confound assessment, and often requires several examinations over a period of observation. Nasal congestion can also confound the clinical assessment. Nasal suctioning might help to ascertain which findings are truly from the lower airways. Fever can be present in about a third of infants with bronchiolitis, but it is usually present early in the illness with a temperature less than 39°C. The median duration of symptoms is about 2 weeks, with 10–20% of infants still having symptoms at 3 weeks after onset. Various clinical scores have been shown in studies and clinical protocols to correlate with disease severity and improvement. Although documentation of a score can be useful as an objective measure, individual scores are not highly predictive, and they should be repeated and combined with other measures of severity for a universal assessment to guide decision making.

The differential diagnosis for bronchiolitis includes considerations of various infectious and non-infectious causes. Absence of upper respiratory symptoms should raise suspicion of other causes of respiratory distress in young infants, including cardiac disease, congenital airway abnormalities such as a vascular ring, or foreign body aspiration. Other infections can resemble or complicate bronchiolitis. Pertussis should be considered in infants with severe or paroxysmal cough, or with body aspiration. Other infections complicating viral bronchiolitis, including otitis media or pneumonia, might present as a new fever or worsening status later in the course of illness.

Various risk factors have been associated with progression to severe bronchiolitis. Those supported by the strongest evidence include presence of chronic lung disease of prematurity and haemodynamically important congenital heart disease, with immunodeficiency and neuromuscular disorders also considered as high risk in practice guidelines. Young infants (aged <2–3 months) and those with a history of premature birth (especially <32 weeks’ gestation) are also at high risk for progression and can present with apnoea without other clinical findings. Studies assessing the risk for further apnoea in hospital have found it to be limited to infants less than 1 month for full-term infants, 48 weeks postconceptional age for preterm infants, or those with apnoea observed before admission.

Appropriate use of pulse oximetry monitoring and initiation of oxygen for bronchiolitis have received increasing attention in studies and practice guidelines. Findings suggest that arbitrary thresholds for oxygen administration might drive hospital admissions and prolong hospital length of stay. These outcomes represent only part of the morbidity of bronchiolitis, but developing evidence suggests that intermittent hypoxaemia might occur commonly in otherwise stable infants with bronchiolitis and raises questions as to whether this factor should be used as a sole indication for admission to hospitals. A Canadian randomised trial found reduced admissions to hospital from the emergency department without any increase in revisits when pulse oximeters displayed values 3% higher than the actual value, suggesting that arbitrary pulse oximetry thresholds result in unnecessary admissions. A similar trial in the UK in the hospital setting found that reduction of the oxygen threshold from 94% to 90% resulted in earlier discharge from the hospital without any evidence of adverse outcomes.

A US trial comparing intermittent versus continuous pulse oximetry in non-hypoxaemic infants in hospitals found similar outcomes between the groups. This US trial and other evidence supports recommendations in US practice guidelines that clinicians use a threshold of 90% for initiation of oxygen, whereas UK guidelines recommend 92%. As the child improves, reduction in intensity of monitoring to intermittent checks is appropriate. A recent study using blinded oximetry at home showed that a substantial proportion of infants with bronchiolitis who are otherwise doing well have oxygen desaturations less than 90%, particularly during sleep, further calling into question arbitrary thresholds for hospital admissions and initiation of oxygen. This evidence will probably lead to efforts to reduce continuous monitoring in children without other indications for monitoring.

**Imaging**

The majority of children with bronchiolitis have either normal radiographs or radiographic findings consistent with simple bronchiolitis, including peribronchial thickening, hyperinflation, and atelectasis. One prospective study of routine radiographs as part of the assessment for bronchiolitis in the emergency department reported airspace disease in 17 (7%) of 246 patients. Despite the low prevalence of radiographic pneumonia, this and other studies have reported an increase in antibiotic prescription after radiographs are performed, because of non-specific findings that influence clinicians’ decisions. Factors that have been associated with definite focal infiltrates consistent with pneumonia include hypoxia (oxygen saturation <92%), grunting, persistently focal crackles, and fever (especially >39°C). Chest radiographs should only be considered in patients when the presentation is not classic for bronchiolitis. These situations include when...
### Diagnostic testing

|               | NIKE (UK), 2015<sup>20</sup> | AAP (USA), 2014<sup>21</sup> | CPS (Canada), 2014<sup>22</sup> | SIGN (Scotland), 2006<sup>23</sup> | Italy, 2014<sup>24</sup> | Spain, 2010<sup>25</sup> | Australia, 2008<sup>26</sup> | France, 2013<sup>27</sup> |
|---------------|-------------------------------|-----------------------------|-------------------------------|--------------------------------|-----------------------|------------------------|------------------------|------------------------|
| **Pulse oximetry** | No mention about continuous use; intermittent checks should be performed in all children | Not recommended if supplemental oxygen is not required, or if oxyhaemoglobin saturation >90% | Not recommended unless high-risk patients in acute phase of disease; intermittent checks appropriate | Intermittent pulse oximetry should be performed on every child who presents to hospital | No mention | Intermittent pulse oximetry; no clear recommendation for continuous monitoring | No mention | No mention |
| **Chest radiography** | Not routinely recommended; consider when intensive care is proposed | Not routinely recommended; consider in severe disease requiring intensive care unit care or signs of airway complication (eg, pneumonia) | Not routinely recommended; consider when diagnosis is unclear, rate of improvement not as expected, or disease severity indicates other diagnoses | Not routinely recommended | Not routinely recommended | Not routinely recommended; might be warranted if diagnostic uncertainty, atypical presentation, severe respiratory distress, or high risk for severe illness | Not routinely recommended | Not routinely recommended |
| **Viral testing** | No mention | Not routinely recommended | Not routinely recommended | Rapid respiratory syncytial virus testing recommended for admitted infants to guide cohorting | Respiratory syncytial virus antigen recommended in hospital setting for cohorting and potentially decreasing antibiotic use | Not routinely recommended; respiratory syncytial virus testing might assist with cohorting | Not routinely recommended; consider if diagnostic uncertainty or young febrile infants | Not routinely recommended |
| **Complete blood count** | Not routinely recommended | Not recommended | Not recommended | Not recommended | Not routinely recommended | Not recommended | No mention | Obtain if undergoing septic work-up |
| **Blood gas** | Not routinely recommended, only if concerning for severe worsening respiratory distress or impending respiratory failure | Not routinely recommended, only if concern for respiratory failure | Not routinely recommended, only if concern for respiratory failure | Not routinely recommended; consider in severe distress or impending respiratory failure | Not routinely recommended; might be useful for severe distress or impending respiratory failure | Not routinely recommended | Not routinely recommended | No mention |
| **Bacterial cultures** | Not routinely recommended | Not mention | Not routinely recommended | Not routinely recommended | Not routinely recommended | Not routinely recommended | Not routinely recommended | Not routinely recommended |

### Treatments

|               | NIKE (UK), 2015<sup>20</sup> | AAP (USA), 2014<sup>21</sup> | CPS (Canada), 2014<sup>22</sup> | SIGN (Scotland), 2006<sup>23</sup> | Italy, 2014<sup>24</sup> | Spain, 2010<sup>25</sup> | Australia, 2008<sup>26</sup> | France, 2013<sup>27</sup> |
|---------------|-------------------------------|-----------------------------|-------------------------------|--------------------------------|-----------------------|------------------------|------------------------|------------------------|
| **β-agonist bronchodilators** | Not recommended | Not recommended | Not recommended | Not recommended | Not routinely recommended; carefully monitored trial might be appropriate | Not routinely recommended | Not recommended | Not recommended |
| **Epinephrine** | Not recommended | Not recommended | Not recommended | Not recommended | Not recommended | Not recommended | Not recommended | Not recommended |
| **Corticosteroids** | Not recommended | Not recommended | Not recommended | Not recommended | Not recommended | Not recommended | Not recommended | Not recommended |

(Table continues on next page)
### Table: National clinical practice guidelines for bronchiolitis

| NICE (UK), 2015<sup>a</sup> | AAP (USA), 2014<sup>b</sup> | CPS (Canada), 2014<sup>c</sup> | SIGN (Scotland), 2006<sup>d</sup> | Italy, 2014<sup>e</sup> | Spain, 2010<sup>f</sup> | Australia, 2008<sup>g</sup> | France, 2013<sup>h</sup> |
|----------------------------|-----------------------------|-------------------------------|-------------------------------|-----------------|------------------|-------------------------|-------------------------|
| **Hypertonic saline** (nebulised) | Not recommended | Not recommended in emergency department; weak recommendation for inpatients in hospitals with average inpatient length of stay >72 h | No mention | Recommended | No mention | Recommended for inpatients | Recommended for inpatients who are moderate to severe |
| **Suctioning** | Do not routinely perform; consider upper airway suctioning in those with respiratory distress or feeding difficulties due to upper airway sections; use if apnoea present | Insufficient data; routine use of deep suctioning might not be beneficial | Superficial nasal suctioning at frequent intervals; avoid deep suctioning and long intervals between suctioning | Use nasal suction to clear secretions if respiratory distress due to nasal blockage | Superficial suctioning recommended; deep suctioning not recommended | Superficial nasal suctioning recommended before feeding, sleeping, and assessment | Might be trialled if nasal congestion |
| **Supplemental oxygen** | Use if oxygen saturation is persistently <92% | Not recommended if oxyhaemoglobin saturation >90% without acidosis | Use if oxyhaemoglobin saturation <90% to maintain saturations ≥90% | Use of oxygen saturation ≥92% or severe respiratory distress | Use if oxygen saturation is persistently <90–92% | Use severe respiratory distress or oxygen saturation <92% | Use if oxygen saturation <92%, or <95% if signs of severe respiratory distress |
| **Chest physiotherapy** | Not routinely recommended unless relevant comorbidities present (eg, spinal muscular atrophy) | Not recommended | Not recommended in infants not admitted to intensive care | Not recommended | Not recommended | Not routinely recommended | Not recommended unless relevant comorbidities (eg, muscular dystrophy or cystic fibrosis), or profound difficulty ventilating |
| **Antibiotic therapy** | Not recommended unless strong suspicion or definite concomitant bacterial infection | Not recommended unless clear and documented evidence of secondary bacterial infection | Not recommended unless clear and documented evidence of secondary bacterial infection | Not recommended unless clear bacterial infection | Not recommended; consider with signs of secondary bacterial infection | Not recommended | Not recommended unless signs of secondary bacterial infection with ventilation |
| **Antiviral therapy** (ie, ribavirin) | No mention | No mention | Not recommended | Not recommended | Not recommended | Not recommended; might be a role for ribavirin in severely immunocompromised patients | No mention |
| **Cool mist or saline aerosol** | No mention | No mention | Not recommended | No mention | Insufficient evidence | Not recommended | No mention |
| **Nutrition or hydration** | Nasogastric or orogastric fluids first in infants who cannot maintain oral hydration; isotonic intravenous fluids in those who cannot tolerate nasogastric or orogastric, or impending respiratory failure | Nasogastric or intravenous fluids for infants who cannot maintain hydration | Consider nasogastric hydration (over intravenous) if difficulty maintaining hydration | Nasogastric or intravenous fluids for infants who cannot maintain hydration | Nasogastric or intravenous fluids for infants who cannot maintain hydration | Nasogastric or intravenous fluids for infants who cannot maintain hydration | Nasogastric or intravenous fluids for infants who cannot maintain hydration |

**AAP**=American Academy of Pediatrics. **CPS**=Canadian Pediatric Society. **NICE**=National Institute for Health and Care Excellence. **SIGN**=Scottish Intercollegiate Guidelines Network. **SiADH**=syndrome of inappropriate antidiuretic hormone excretion.

<sup>a</sup> A systematic review of the evidence for bronchiolitis was undertaken, and guidelines were developed by the Multidisciplinary Care of Bronchiolitis Group. See www.careofbronchiolitis.org for further information. These guidelines are based on the systematic review and consultation with key stakeholders. The recommendations will be reviewed annually as new evidence becomes available.

<sup>b</sup> Adapted from Neuhaus et al. (2010) [23] (Continued from previous page)

<sup>c</sup> Adapted from Koopmans et al. (2010) [24]

<sup>d</sup> Adapted from van Kooten et al. (2007) [25]

<sup>e</sup> Adapted from Piazza et al. (2014) [26]

<sup>f</sup> Adapted from Almagro et al. (2010) [27]

<sup>g</sup> Adapted from Bellamy et al. (2008) [28]

<sup>h</sup> Adapted from Leclerc et al. (2013) [29]
another diagnosis (such as foreign body aspiration) is high on the differential diagnosis, when a child is severely ill and respiratory failure is imminent, and when symptoms are progressing or not resolving according to the typical disease course expected for bronchiolitis.

Lung ultrasound is increasingly used to assess cardiopulmonary conditions in adults and children. Several studies have investigated the use of lung ultrasound in the diagnosis of bronchiolitis. Two small studies found that ultrasound findings in infants with bronchiolitis correlate with clinical findings, and might be more specific than chest radiography.43,62 but further studies are needed to establish whether there is a role for ultrasound in diagnosis or assessment of severity.

Viral testing
With the development of PCR to detect respiratory viruses in the nasopharynx, interest in the use of viral testing for causative diagnosis in bronchiolitis has increased. Virological testing, however, does not generally assist in management and is insufficient to predict outcomes.20,63 Many national guidelines therefore recommend against routine virological testing in bronchiolitis (table). Recent studies suggest that higher respiratory syncytial virus genomic load, measured using quantitative PCR, might be associated with increased length of stay, use of respiratory support, and need for intensive care, in addition to recurrent wheezing, compared with lower viral loads.28,31,32,64 Further study is warranted to confirm this association and clarify whether viral load measurement improves understanding of disease pathophysiology and severity. Several guidelines recommend using respiratory syncytial virus testing to guide cohorting of patients; however, the viruses most likely to cause bronchiolitis are all transmitted in a similar fashion (close contact with large-particle aerosols or direct contact with contaminated fomites).52–67 Thus, infection control might not be dependent on the identification of specific viruses, but rather on following strict precautions including hand hygiene, separating infants in shared hospital rooms by more than 1 m, and other infection control procedures.66 Additionally, given the sensitivity of PCR testing, results should be interpreted with caution. Certain viruses, such as rhinovirus, might be detected because of viral shedding from an unrelated illness or colonisation; whereas certain other viruses, such as respiratory syncytial virus and metapneumovirus, are almost always associated with an acute infection.

Blood and urine testing
Blood and urine testing is not routinely recommended as part of standard practice in the diagnostic work-up of bronchiolitis (table). A blood gas measurement should not be routinely obtained in infants with bronchiolitis, unless there are signs of impending respiratory failure or severe distress. Proportions of serious bacterial infections, especially bacteraemia and meningitis, are very low in infants with bronchiolitis.48 Abnormal white blood cell count is rarely useful in predicting serious bacterial infections in children infected with respiratory syncytial virus.49 Guidelines universally do not recommend complete blood counts in infants with bronchiolitis unless blood count is part of assessment for a fever in infants younger than 1–2 months. Similarly, given that bacteraemia is exceedingly rare (with cited proportions of <0.1% in the post-pneumococcal vaccine era), blood cultures should not be routinely performed, except in the septic work-up of infants younger than 1–2 months,60 or in those with severe illness and signs of sepsis. Hydration status is an important consideration in infants with bronchiolitis and should be determined by clinical examination. Routine measurement of serum electrolytes is of little value in the majority of infants.

Urinary tract infections in infants with bronchiolitis occur with greater frequency than do bacteraemia and meningitis, with proportions ranging from 1% to 7%.60,70,72 It is reasonable to obtain a urinalysis and urine culture for infants aged less than 60 days with fever and for older febrile infants who have risk factors for urinary tract infections,73 but urine should not be routinely obtained in all infants with bronchiolitis.

Management
Bronchodilators
Current recommendations for management of bronchiolitis focus on agents to treat the pathophysiological effects of viral lower respiratory infection (eg, bronchodilators and hypertonic saline). Specific antivirals such as ribavirin to treat respiratory syncytial virus infection are not recommended in practice guidelines for typical cases of bronchiolitis because of challenging delivery methods, high cost, and potential health risks to caregivers. Multiple new agents for prevention and treatment are under investigation and might become available in the future, including immunoglobulins, small interfering RNA interference, fusion inhibitors, and small molecules.74

Numerous studies have assessed the role of bronchodilators for the treatment of bronchiolitis, and systematic reviews have found no consistent benefit. A 2014 Cochrane Collaboration systematic review identified 30 studies assessing bronchodilators, predominantly salbutamol and excluding epinephrine, and 21 studies that looked specifically at clinical scores found no evidence of benefit in any outcomes for infants admitted to hospitals.75 In outpatients, oxygen saturation, admission to hospital, or time to resolution of symptoms did not improve with bronchodilator usage compared with placebo. For outpatient studies assessing short-term change in pooled clinical scores, the reviewers found a small significant difference in mean score (Z=2.26; p=0.024) that was of small effect with minimal clinical importance (figure 2). Outpatient studies were
heterogeneous \( (P=81\%; p<0.00001) \), and those showing benefit in scores tended to include older children and children with recurrent wheeze.

Nebulised epinephrine was assessed in another Cochrane Collaboration systematic review. This review found no benefit for epinephrine compared with placebo for inpatients in hospital length of stay or other outcomes. A multicentre Scandinavian study published after this Cochrane review found that inpatients receiving standing doses of epinephrine had longer length of stay compared with inpatients receiving as-needed epinephrine or placebo. For outpatients, the Cochrane review found a difference in the numbers of admissions associated with epinephrine treatment during the time of an emergency department visit, but not during the overall course of illness when assessed at 1 week. Clinical practice guidelines including those from the USA, UK, and Canada do not recommend treatment with bronchodilators for bronchiolitis because of this evidence (table). Nebulised hypertonic saline

Nebulised hypertonic saline is thought to reduce airway oedema, decrease mucus plugging, improve mucociliary clearance, and rehydrate the airway surface liquid in infants with bronchiolitis. These physiological changes are extrapolated from the cystic fibrosis literature, and the pathophysiological processes in acute bronchiolitis are different. Therefore, the theoretical benefits of hypertonic saline seen in cystic fibrosis might not be present in infants with acute viral bronchiolitis. Although initial trials demonstrated some ability of hypertonic saline to decrease hospital length of stay and transiently improve clinical severity score, more recent trials demonstrated conflicting results. The trials that showed the largest benefit were done in hospitals with lengths of stay approaches or exceeds 72 h; thus, hypertonic saline for infants in countries and institutions in which the length of stay approaches or exceeds 72 h might be beneficial at reducing length of stay. The conflicting results are

| Bronchodilator | Placebo | Weight | Mean difference (95% CI) |
|---------------|---------|--------|-------------------------|
| N             | Mean (SD) | N     | Mean (SD)             |
| Inpatient studies | | | |
| Goh (1997) | 60 | 3.2 (1.7) | 29 | 3.1 (1.8) | 5.6% | 0.06 (0.39 to 0.50) |
| Gurkan (2004) | 18 | 4.2 (0.8) | 12 | 4.7 (0.8) | 4.2% | -0.61 (-1.06 to 0.14) |
| Karaday (2005) | 22 | 4.9 (1.8) | 11 | 5.3 (1.4) | 4.3% | -0.23 (-0.96 to 0.49) |
| Karaday (2005) | 24 | 4.1 (1.4) | 12 | 5.3 (1.4) | 4.3% | -0.84 (-1.56 to -0.12) |
| Patel (2002) | 51 | 3.3 (2.86) | 48 | 6.37 (3.00) | 5.8% | -0.28 (-0.68 to 0.11) |
| Scarfett (2012) | 10 | 4.9 (2.9) | 10 | 2.8 (2.2) | 3.5% | 0.78 (-0.17 to 1.20) |
| Tims (2009) | 16 | 4.7 (2.4) | 19 | 4.6 (1.3) | 4.5% | 0.05 (-0.61 to 0.72) |
| Totapally (2002) | 10 | 0.95 (0.71) | 9 | 0.58 (0.77) | 3.5% | 0.48 (-0.44 to 1.39) |
| Wang (1992) | 38 | 2.8 (1.5) | 17 | 3.2 (1.7) | 5.0% | -0.25 (-0.83 to 0.32) |
| Subtotal | 249 | 167 | 40.5% | -0.14 (-0.41 to 0.12) |
| Outpatient studies | | | |
| Alano (1992) | 17 | 17.5 (4.2) | 20 | 22.4 (5.1) | 4.4% | -1.02 (-1.71 to -0.33) |
| Avril (2013) | 36 | 1.5 (1.4) | 18 | 1.8 (1.4) | 5.0% | -0.21 (-0.78 to 0.36) |
| Avril (2016) | 36 | 2.3 (0.9) | 19 | 1.8 (1.4) | 5.0% | 0.45 (-0.11 to 0.11) |
| Can (1998) | 52 | 5.2 (1.8) | 52 | 10.2 (2.5) | 5.5% | -1.78 (-3.24 to -0.33) |
| Gadomski (1994) (neb) | 32 | 3.8 (2.5) | 32 | 9.5 (6.2) | 5.3% | -0.16 (-0.65 to 0.33) |
| Gadomski (1994) (oral) | 32 | 10.1 (6.0) | 32 | 12.4 (7.1) | 5.3% | -0.35 (-0.84 to 0.15) |
| Gadomski (1994b) (neb) | 21 | 4.0 (3.0) | 18 | 5.0 (3.0) | 4.7% | -0.33 (-0.96 to 0.31) |
| Gadomski (1994b) (oral) | 15 | 4.0 (3.0) | 22 | 6.0 (4.9) | 4.5% | -0.54 (-2.13 to 0.13) |
| Ipok (2011) | 30 | 3.10 (2.43) | 30 | 2.47 (2.16) | 5.3% | 0.27 (-0.24 to 0.78) |
| Klasson (1991) | 42 | 5.0 (2.9) | 41 | 6.2 (2.2) | 5.6% | -0.39 (-0.82 to 0.10) |
| Ralston (2005) | 23 | 6.39 (2.43) | 25 | 7.00 (2.84) | 5.0% | -0.21 (-0.79 to -0.34) |
| Schweig (1992) | 13 | 3.8 (2.8) | 12 | 6.6 (3.5) | 3.8% | -0.86 (-1.68 to 0.03) |
| Subtotal | 349 | 321 | 59.5% | -0.42 (-0.79 to -0.06) |
| Overall | 598 | 488 | 100.0% | -0.30 (-0.54 to -0.05) |

Figure 2: Meta-analysis of studies assessing average clinical score after treatment in patients with bronchiolitis receiving bronchodilators versus placebo

Test for heterogeneity in the inpatient studies demonstrated low inconsistency between the nine studies \( (I^2=36\%; p=0.13) \) and the summary effect was not significant \( (Z=1.06; p=0.29) \), the outpatient studies demonstrated very high inconsistency between the 12 studies \( (I^2=81\%; p<0.00001) \) and the summary effect was significant \( (Z=2.26; p=0.024) \), and the overall heterogeneity of the meta-analysis demonstrated high inconsistency between the 21 studies \( (I^2=73\%; p=0.00001) \) and the overall summary effect was significant \( (Z=2.4; p=0.016) \). IPR = ipratropium. SAL = salbutamol. neb = nebulised. Reproduced from Gadomski and Scribani by permission of John Wiley and Sons.

www.thelancet.com Vol 389 January 14, 2017 217
reflected in the differences in recommendations across national guidelines (table), with some countries not recommending hypertonic saline, some recommending use for all inpatients, and some recommending use only in moderate to severe illness.

The largest systematic review and meta-analysis, published in 2015, examined 24 trials and 3209 patients.\textsuperscript{31} Infants receiving hypertonic saline had a significant difference in hospital length of stay of −0·45 days (95% CI −0·5 to −0·22; p=0·001) in those who received hypertonic saline (figure 3).\textsuperscript{32} This study found a discrepancy between the overall combined effect of all studies on length of stay and the negative results from the largest trials, allowing the authors to conclude that neither individual trials nor pooled estimates provide a strong evidence-based foundation for the use of hypertonic saline. Both meta-analyses showed substantial heterogeneity across studies (I\textsuperscript{2}=82·1%, p<0·001;\textsuperscript{91} and I\textsuperscript{2}=77·8%, p=0·02992). A recent reanalysis of the first 2015 meta-analysis removed two outlying Chinese studies and accounted for imbalances in day of illness at presentation.\textsuperscript{93} These analyses resolved the heterogeneity and found that hypertonic saline does not reduce length of stay in infants admitted to hospitals with bronchiolitis (mean difference in length of stay accounting for day of illness imbalance −0·36 days; 95% CI −0·5 to −0·22; p=0·001) in those who received hypertonic saline.\textsuperscript{93}
length of stay after adjustment for outliers and imbalances. The decision to undertake future trials is controversial given the positive results of some meta-analyses and negative results of others.

**Corticosteroids**

Multiple studies have examined the role of corticosteroids in the management of children with bronchiolitis. Data from two large multicentre trials have shown no benefit to corticosteroids alone in reducing admissions to hospital, and a 2013 Cochrane Collaboration review supports the results of these studies. This review included only studies that enrolled children younger than 24 months with a first episode of wheezing and signs of a viral illness. Among the included eight outpatient studies comparing corticosteroids with placebo there was no reduction in admission at day 1 (Z=1.05; p=0.30) and day 7 (Z=1.38; p=0.17) after enrolment (figure 4), clinical scores, length of stay in the emergency department, or length of time to resolution of symptoms. Among the nine inpatient studies (772 participants), length of hospital stay was not reduced. On the basis of this evidence, multiple clinical practice guidelines recommend against the use of corticosteroids for infants with bronchiolitis (table). Although clinicians report considering a family or personal history of atopy when deciding whether to treat infants with bronchiolitis with corticosteroids, there is no evidence that such infants receive any benefit from corticosteroid treatment. Evidence for the presence or absence of respiratory syncytial virus infection in these infants being associated with a response to corticosteroids is also unavailable. Authors from a large study with a factorial design have suggested, in an unadjusted analysis, that high-dose corticosteroids in combination with nebulised epinephrine might reduce admissions for outpatients with bronchiolitis by day 7, but these results are considered exploratory.

**High-flow oxygen and respiratory support**

Non-invasive technologies to improve oxygenation and ventilation for bronchiolitis include humidified high-flow nasal cannula oxygen and continuous positive airway pressure. High-flow nasal cannula allows delivery of high flows (usually 1–2 L/kg per min) with humidification and a cannula designed to improve patient tolerance. It has been used widely in premature infants, but the mechanisms of action are unclear, in particular whether it might deliver positive end-expiratory pressure in some conditions.
improved respiratory parameters and reduced intubation rates after implementation.97 One small randomised trial compared high-flow nasal cannula with hypertonic saline and found no difference in change in respiratory score.108 Concerns about high-flow nasal cannula include the potential for rapid deterioration if the infant is not closely monitored and costs associated with overuse.

Continuous positive airway pressure has been studied in intensive care settings in observational studies and several small trials, with some evidence of improved respiratory parameters.95 The UK guidelines recommend considering continuous positive airway pressure in children with impending respiratory failure from bronchiolitis.

Antibiotics
Antibiotic overuse in children with bronchiolitis probably occurs because of concerns about the presence of fever, the young age of affected patients, difficulty differentiating atelectasis from infectious consolidation on chest radiograph, and concern for undetected secondary bacterial infection. Bronchiolitis, however, has a clear viral cause and the occurrence of secondary bacterial infections is low, with a risk of bacteraemia or meningitis of less than 1%.109 A detailed review of randomised clinical trials found that routine use of antibiotics did not improve duration of symptoms, length of hospital stay, need for oxygen therapy, or hospital admission.110 Overuse of antibiotics is known to result in unnecessary adverse effects on the patient, and the development of antimicrobial resistance. Routine use should be avoided unless there is clear evidence of a secondary bacterial infection (table). Acute otitis media has been documented in up to 60% of infants with bronchiolitis.106,107 Antibiotic use for acute otitis media in bronchiolitis should follow established evidence and guidelines for acute otitis media.108

Macrolide antibiotics have anti-inflammatory properties that might have potential benefit in mitigating the inflammation present in bronchiolitis. Two randomised trials found that there was no difference between azithromycin and placebo in hospital length of stay, need for oxygen, or hospital re-admission.108,109 Another randomised trial found that azithromycin lowered nasal interleukin-8 concentrations, prolonged time to subsequent wheezing episodes, and resulted in fewer days with respiratory symptoms in the year following the bronchiolitis episode compared with placebo.110 Finally, a US multicentre study found that in children aged 12–72 months with a history of recurrent severe lower respiratory tract infections, early administration of azithromycin during a lower respiratory tract infection reduced the likelihood of progression to a severe infection, but it is not clear whether the underlying disease in these children was bronchiolitis or some other disease process.109 Given the current evidence, routine use of macrolides is not recommended in bronchiolitis and more research is needed to clarify any potential role it might have in the future.

Supportive therapies
Hydration, suctioning, and chest physiotherapy have been suggested as supportive therapies. Infants with bronchiolitis might have difficulty feeding because of nasal congestion and increased work of breathing; thus, hydration remains a cornerstone of therapy. A multicentre study of 759 infants younger than 12 months admitted to hospital with bronchiolitis showed no benefit of intravenous fluids compared with administration of fluids by nasogastric tube in mean length of stay, admission to the intensive care unit, need for ventilatory support, and adverse events. This trial also found that a nasogastric tube might be easier to place than an intravenous line in these infants.110 Most guidelines recommend either nasogastric or intravenous fluids to maintain hydration, with the UK and Scottish guidelines preferring nasogastric or orogastric hydration in those that can tolerate it compared with intravenous hydration (table). If intravenous fluids are used, isotonic fluids are preferred to avoid risk of hyponatraemia.18 Because infants are obligate nasal breathers, nasal suctioning has been suggested to help with clearing of the nares, improve the work of breathing, and improve feeding; however, suctioning might irritate the nasal mucosa and result in oedema. No randomised controlled trials have examined the role of nasal suctioning in bronchiolitis. The insufficient available evidence includes a retrospective cohort study of 740 infants112 and a small observational study of 40 infants.113 These studies suggest that deep suctioning might increase length of stay for inpatients,112 infrequent suctioning is associated with an increased length of stay,113 and oxygen saturation might increase after suctioning.113 To draw conclusions about causality from these observational studies is difficult, because the potential for confounding by indication exists (eg, sicker children might be more likely to receive deep suctioning). Evidence suggests that oxygen saturation increases after nasal irrigation even without suctioning.108 Current guidelines give differing recommendations with regard to suctioning; those that support its use recommend only superficial suctioning rather than deep suctioning (table).18,114,115

Chest physiotherapy use in bronchiolitis appears to vary by country.101 A recent Cochrane Collaboration review of 12 studies (1249 participants) demonstrated no evidence of benefit to any type of chest physiotherapy among inpatients in length of stay, oxygen saturation, or respiratory parameters.116 No published guidelines routinely recommend chest physiotherapy for the management of uncomplicated bronchiolitis in otherwise healthy children without respiratory comorbidities (table).18,114,115

Prognosis
Much work has been published about the risk of developing recurrent wheezing and asthma following bronchiolitis in infancy.117–126 Studies have followed birth cohorts to determine the risk of subsequent wheezing
after lower respiratory tract infection in young childhood, and cohorts of children admitted to hospital with bronchiolitis.14-17 Overall, admission to hospital with bronchiolitis at a young age is associated with an increased risk of recurrent wheezing. Studies report that 17–60% of children with bronchiolitis might develop recurrent wheezing in the years following their initial admission to hospital. A large study from Taiwan that followed up 1981 children admitted with bronchiolitis before age 3 years found that by age 10 years, 351 (17.7%) of 1981 children with bronchiolitis had a diagnosis of asthma compared with 2159 (11.7%) of 18527 controls (hazard ratio 1.58; 95% CI 1.41–1.71).18 One small cohort study of 138 patients has suggested that 18 (39%) of 46 children admitted with bronchiolitis before 12 months have asthma by 18 years compared with eight (9%) of 92 controls.19 However, another study that followed a birth cohort of 1246 children found that although lower respiratory tract infection in childhood was associated with an increased risk of recurrent wheezing, this association decreased with age and was not significant by age 13 years.20 Most children in this cohort had mild illness not requiring hospital admission, and severity of illness might be associated with the increased risk of asthma.21 The question remains whether respiratory infection at a young age itself predisposes children to asthma through damage or alteration of lung function, or whether children with severe bronchiolitis might have individual risk factors (such as altered immune response or airway function) that predisposes them to both severe bronchiolitis and recurrent wheezing.8

Knowledge gaps and controversies

Substantial knowledge gaps and controversies exist in the management of acute bronchiolitis. The role of nebulised hypertonic saline in acute management is not clear, resulting in conflicting recommendations across clinical guidelines (table). Although meta-analyses suggest a small reduction in length of stay, these analyses are limited by heterogeneity, not accounting for duration of illness, and not considering the role of outlying study populations.14 Two large multicentre trials do not support a clinically significant difference in length of stay for inpatients and there is no clear evidence of cost benefit.19-21 While the same meta-analysis suggests a possible reduction in admissions for outpatients, the confidence intervals were wide and the studies were also heterogeneous.13 No multicentre studies of nebulised hypertonic saline have been completed in outpatients. Although the evidence is increasing that hypertonic saline has little role in meaningfully reducing the length of stay, its role in outpatients is less clear. A large outpatient multicentre study could clarify whether there is any benefit.

Evidence also suggests that combined therapy with nebulised epinephrine and corticosteroids might reduce admissions to hospital.22 Synergy between corticosteroids and β2 agonists is well documented in clinical trials of asthma management.23-26 Basic science literature also shows that β2 agonists and corticosteroids enhance each other’s effectiveness, particularly with regard to anti-inflammatory gene expression.27-29 Because of the economic burden of bronchiolitis and the plausible basic and clinical evidence for synergy, a large and multicentre trial is needed to ascertain whether combined therapy with epinephrine and corticosteroids is beneficial.

Oxygen saturation and the use of pulse oximetry play an important role in the decision to admit infants with bronchiolitis to hospital and in the length of their hospital stay.30-37 Clinical practice guidelines also give conflicting guidance on the level of oxygen saturation at which admission should be considered. Furthermore, a substantial proportion of discharged infants have episodes of transient desaturation.38 Again, in view of the large health-care costs associated with hospital admission in bronchiolitis, further research is needed to clarify the level of oxygen saturation requiring admission, the role of continuous and spot measurements of oxygen saturation, and the clinical importance of transient desaturations in otherwise stable young infants.

Contributors

TAF contributed to the design and coordinated the writing of this manuscript. All authors contributed to the literature search and writing of this manuscript.

Declarations of interest

We declare no competing interests. TAF, ACP, and JJZ have participated in trials of bronchiolitis funded by unrestricted public or academic institutional funding sources that had no influence on the conception and writing of this manuscript.

Acknowledgments

TAF receives funding from the National Institutes of Health—National Institute of Allergy and Infectious Diseases (grant 1K23AI121325-01). The NIH had no role in the writing of this manuscript, and in the decision to submit the paper for publication. We would like to thank Kerry Aicholtz for her administrative support.

References

1 Kyu HH, Pinho C, Wagner JA, et al. Global and national burden of diseases and injuries among children and adolescents between 1990 and 2013: findings from the Global Burden of Disease 2013 Study. JAMA Pediatr 2016; 170: 267–87.
2 Nair H, Nokes DJ, Gesner BD, et al. Global burden of acute lower respiratory infections due to respiratory syncytial virus in young children: a systematic review and meta-analysis. Lancet 2010; 375: 1545–55.
3 Pfruntner A, Wier L, Stocks C. Most frequent conditions in US hospitals, 2010. HCUP Statistical Brief #148, 2011. http://www.hcup-us.ahrq.gov/reports/statbriefs/sb148.pdf (accessed March 30, 2016).
4 Hasegawa K, Tsugawa Y, Brown DF, Mansbach JM, Camargo CA Jr. Temporal trends in emergency department visits for bronchiolitis in the United States, 2006 to 2013. Pediatr Infect Dis J 2014; 33: 11–18.
5 Hasegawa K, Tsugawa Y, Brown DF, Mansbach JM, Camargo CA Jr. Trends in bronchiolitis hospitalizations in the United States, 2000–2009. Pediatrics 2011; 133: 28–36.
6 Haynes AK, Prill MM, Iwane MK, Gerber SI. Respiratory syncytial virus—United States, July 2012–June 2014. MMWR Morb Mortal Wkly Rep 2014; 63: 1133–36.
7 Haynes AK, Manangan AP, Iwane MK, et al. Respiratory syncytial virus circulation in seven countries with Global Disease Detection Regional Centers. J Infect Dis 2013; 208 (suppl 3): S246–54.

www.thelancet.com Vol 389 January 14, 2017 221
Mansbach JM, Piedra PA, Teach SJ, et al. Prospective multicenter study of respiratory syncytial virus genomic load and disease severity among children hospitalized with bronchiolitis: multicenter cohort studies in the United States and Finland. J Infect Dis 2015; 211: 1550–59.

Scagnoli C, Midulla F, Selvaggi C, et al. Evaluation of viral load in infants hospitalized with bronchiolitis caused by respiratory syncytial virus. Med Microbiol Immunol (Berl) 2012; 201: 111–17.

Papadopoulos NG, Moustaki M, Toslia M, et al. Association of rhinovirus infection with increased disease severity in acute bronchiolitis. Am J Respir Crit Care Med 2002; 165: 1285–89.

Seemple MG, Cowell A, Dove W, et al. Dual infection of infants by human metapneumovirus and human respiratory syncytial virus is strongly associated with severe bronchiolitis. J Infect Dis 2005; 191: 382–86.

Jansen RR, Wieringa J, Koekemoer SM, et al. Frequent detection of respiratory viruses without symptoms: toward defining clinically relevant cutoff values. J Clin Microbiol 2011; 49: 2631–36.

Hasegawa K, Linnewehn RW, Aavahanula V, et al. Detection of respiratory syncytial virus and rhinovirus in healthy infants. BMC Res Notes 2015; 8: 718.

Self WH, Williams DJ, Zhou Y, et al. Respiratory viral detection in children and adults: comparing asymmetric controls and patients with community-acquired pneumonia. J Infect Dis 2016; 213: 584–91.

Bronchiolitis in children: diagnosis and management. NICCE guideline, 2013. https://www.nice.org.uk/Guidance/NG9 (accessed March 30, 2016).

Ralston SL, Lieberthal AS, Meissner HC, et al. Clinical practice guideline: the diagnosis, management, and prevention of bronchiolitis. Pediatrics 2014; 134: e1–642–502.

Court SD. The definition of acute respiratory illnesses in children. Postgrad Med J 1973; 49: 711–726.

Plint AC, Grenon R, Klassen TP, Johnson DW. Bronchodilator and steroid use for the management of bronchiolitis in Canadian pediatric emergency departments. CJEM 2015; 17: 46–53.

Fernandes RM, Plint AC, Terwee CB, et al. Validity of bronchiolitis outcome measures. Pediatrics 2015; 135: e1399–408.

McCallum GB, Morris PS, Wilson CC, et al. Severity scoring systems: are they internally valid, reliable and predictive of oxygen use in children with acute bronchiolitis? Pediatr Pulmonol 2010; 45: 608–13.

Willwert BM, Harper MB, Greenes DS. Identifying hospitalized infants who have bronchiolitis and are at high risk for apnea. Ann Emerg Med 2006; 48: 441–47.

Friedman JN, Rieder MJ, Walton JM. Bronchiolitis: recommendations for diagnosis, monitoring and management of children one to 24 months of age. Paediatr Child Health 2014; 19: 485–98.

Scottish Intercollegiate Guidelines Network (SIGN). Bronchiolitis in children: a national clinical guideline. 2006. http://www.sign.ac.uk/ guidelines/fulltext/91/index.html (accessed March 30, 2016).

Baraldi E, Lanari M, Manzoni P, et al. Inter-society consensus document on treatment and prevention of bronchiolitis in newborns and infants. Ital J Pediatr 2014; 40: 65.

Working Group of the Clinical Practice Guideline on Acute Bronchiolitis. Quality plan for the Spanish national healthcare system of the Spanish Ministry for Health and Social Policy; Catalan Agency for Health Technology Assessment, 2010. Clinical Practice Guidelines in the Spanish National Healthcare System: CAHTA no. 2007/05.

Turren T, Wilkinson F, Harris C, Mazza D. Evidence based guidelines for the management of bronchiolitis. Aust Fam Physician 2008; 37: 6–13.

Verstraete M, Croux P, Gouin M, et al. Prise en charge de la bronchiolite aiguë du nourrisson de moins de 1 an: actualisation et consensus medical au sein des hôpitaux universitaires du Grand Ouest (HUGO). Arch Pediatr 2014; 21: 51–62.

Schuh S, Freedman S, Coates A, et al. Effect of oxymetazoline on hospitalization in bronchiolitis: a randomized clinical trial. JAMA 2014; 312: 712–18.

Cunningham S, Rodriguez A, Adams T, et al. Oxygen saturation targets in infants with bronchiolitis (BIDS): a double-blind, randomised, equivalence trial. Lancet 2015; 386: 1041–48.

McCallie CJ, Urosev M, Ralston S, et al. Use of infant vent vs continuous pulse oximetry for non-hypoxemic infants and young children hospitalized for bronchiolitis: a randomized clinical trial. JAMA Pediatr 2015; 169: 898–904.
67 Brankston G, Gitterman L, Hirji Z, Lemieux C, Gardam M. Effect of oxygen desaturations on subsequent medical visits in infants discharged from the emergency department with bronchiolitis. JAMA Pediatr 2016; 170: 602–08.

55 Mahabee-Gittens EM, Bachman DT, Shapiro ED, Dowd MD. Chest radiographs in the pediatric emergency department for children 0–18 months of age with wheezing. Clin Infect Dis (1999) 38: 395–99.

61 Caiulo VA, Gargani L, Caiulo S, et al. Lung ultrasound in bronchiolitis: comparison with chest X-ray. Eur J Pediatr 2011; 170: 1427–33.

58 Schuh S, Lalani A, Allen U, et al. Evaluation of the utility of racemic adrenaline and inhalation strategies in acute bronchiolitis. Pediatr Pulmonol 2014; 50: 617–19.

56 Mathews B, Shah S, Cleveland RH, Lee EY, Bachur RG, Principi T, Coates AL, Parkin PC, Stephens D, DaSilva Z, Schuh S. Hypertonic saline versus normal saline in inpatient bronchiolitis: a randomized controlled trial. JAMA Pediatr 2014; 168: 657–63.

60 Mandellberg A, Tal G, Wittling M, et al. Nebulized 3% hypertonic saline solution treatment in hospitalized infants with viral bronchiolitis. Chest 2003; 123: 481–87.

82 Kuzel BA, Al-Qadhi SA, Kent S, et al. Nebulized hypertonic saline in the treatment of bronchiolitis in infants. J Pediatr 2007; 151: 266–70.

85 Florin TA, Shaw KN, Kittick M, Yaksoce S, Zorc JJ. Nebulized hypertonic saline for bronchiolitis in the emergency department: a randomized clinical trial. JAMA Pediatr 2014; 168: 664–70.

78 Mandellberg A, Amirav I. Hypertonic saline or high volume normal saline for viral bronchiolitis: mechanisms and rationale. Pediatr Pulmonol 2010; 45: 36–40.

51 Sauer H, Esteban-Cruinani N, Azzarone G, et al. 3% hypertonic saline versus normal saline in inpatient bronchiolitis: a randomized controlled trial. Pediatrics 2015; 136: 1036–43.

59 Librizzi J, McCulloh R, Koehn K, Alverson B. Antibiotics for acute otitis media in children with bronchiolitis. Cochrane Database Syst Rev 2013; 10: CD005189.

57 Librizzi J, McCulloh R, Koehn K, Alverson B. Appropriateness of testing for serious bacterial infection in children hospitalised with bronchiolitis. Hosp Pediatr 2014; 4: 33–38.

52 Librizzi J, McCulloh R, Koehn K, Alverson B. Appropriateness of testing for serious bacterial infection in children hospitalised with bronchiolitis. Hosp Pediatr 2014; 4: 33–38.

65 Hall CB. The spread of influenza and other respiratory viruses: Caiulo VA, Gargani L, Caiulo S, et al. Lung ultrasound in bronchiolitis: comparison with chest X-ray. Eur J Pediatr 2011; 170: 1427–33.

51 Silver AH, Esteban-Cruinani N, Azzarone G, et al. 3% hypertonic saline versus normal saline in inpatient bronchiolitis: a randomized controlled trial. Pediatrics 2015; 136: 1036–43.

58 Schuh S, Lalani A, Allen U, et al. Evaluation of the utility of racemic adrenaline and inhalation strategies in acute bronchiolitis. Pediatr Pulmonol 2014; 50: 617–19.

56 Mathews B, Shah S, Cleveland RH, Lee EY, Bachur RG, Principi T, Coates AL, Parkin PC, Stephens D, DaSilva Z, Schuh S. Hypertonic saline versus normal saline in inpatient bronchiolitis: a randomized controlled trial. JAMA Pediatr 2014; 168: 657–63.

60 Mandellberg A, Tal G, Wittling M, et al. Nebulized 3% hypertonic saline solution treatment in hospitalized infants with viral bronchiolitis. Chest 2003; 123: 481–87.

82 Kuzel BA, Al-Qadhi SA, Kent S, et al. Nebulized hypertonic saline in the treatment of bronchiolitis in infants. J Pediatr 2007; 151: 266–70.

85 Florin TA, Shaw KN, Kittick M, Yaksoce S, Zorc JJ. Nebulized hypertonic saline for bronchiolitis in the emergency department: a randomized clinical trial. JAMA Pediatr 2014; 168: 664–70.

664–70.

657–63.

616–20.

65: 148–80.

52: 377–80.

50: 3211–15.

2015; 31: 636–20.

576–580.

60: 2079–89.

2007: 136: 395–56.

60: 899–900.

588: 964–99.

687–900.

60: 899–900.

60: 899–900.

60: 899–900.

60: 899–900.

60: 899–900.

60: 899–900.

60: 899–900.

60: 899–900.

60: 899–900.

60: 899–900.

60: 899–900.

60: 899–900.

60: 899–900.

60: 899–900.

60: 899–900.

60: 899–900.

60: 899–900.

60: 899–900.

60: 899–900.

60: 899–900.

60: 899–900.

60: 899–900.

60: 899–900.

60: 899–900.

60: 899–900.
103 McCallum GB, Morris PS, Chatfield MD, et al. A single dose of azithromycin does not improve clinical outcomes of children hospitalised with bronchiolitis: a randomised, placebo-controlled trial. *PloS One* 2013; 8: e74316.

104 Pinto LA, Pitezm PM, Luis F, et al. Azithromycin therapy in hospitalized infants with acute bronchiolitis is not associated with better clinical outcomes: a randomised, double-blinded, and placebo-controlled clinical trial. *J Pediatr* 2012; 161: 104–08.

105 Beigelman A, Isaacson-Schmid M, Sajol G, et al. Randomized trial to evaluate azithromycin’s effects on serum and upper airway IL-8 levels and recurrent wheezing in infants with respiratory syncytial virus bronchiolitis. *J Allergy Clin Immunol* 2015; 135: 117–78.

106 Bacharier LB, Guilbert TW, Mauger DT, et al. Early administration of azithromycin and prevention of severe lower respiratory tract illnesses in preschool children with a history of such illnesses: a randomized clinical trial. *JAMA* 2015; 314: 2034-44.

107 Oakley E, Borland M, Neutze J, et al, for the Paediatric Research in Emergency Departments International Collaborative (PREDICT). Nasogastric hydration versus intravenous hydration for infants with bronchiolitis. *JAMA* 2013; 314: 25–30.

108 Mussman GM, Parker MW, Statile A, Sucharew H, Brady PW. Suctioning and length of stay in infants hospitalized with bronchiolitis. *JAMA* 2013; 310: 1176–85.

109 Moschino L, Mario F, Carraro S, Visentin F, Zanconato S, Baraldi E. Is nasal suctioning warranted before measuring O2 saturation in infants with bronchiolitis? *Arch Dis Child* 2016; 101: 114–15.

110 Schreiber S, Ronfani L, Ghirardo S, et al. Nasal irrigation with saline solution significantly improves oxygen saturation in infants with bronchiolitis. *Acta Paediatr* 2016; 105: 292–96.

111 Ralston S, Garber M, Naranj S, et al. Decreasing unnecessary utilization in acute bronchiolitis care: results from the value in pediatrics patient network. *J Hosp Med* 2013; 8: 25–30.

112 Gajdos V, Katsahian S, Beydon G, et al. Effectiveness of chest physiotherapy in infants hospitalised with acute bronchiolitis: a multicenter, randomized, controlled trial. *PloS Med* 2010; 7: e1000345.

113 Roqué i Figuls M, Giné-Garriga M, Granados Rugeles C, Perrotta C, Vilartó J. Chest physiotherapy for acute bronchiolitis in paediatric patients between 0 and 24 months of age. *Cochrane Database Syst Rev* 2016; 2: CD004873.

114 Carlsem KH, Larsen S, Bjerve O, Leegaard J. Acute bronchiolitis: predisposing factors and characterization of infants at risk. *Pediatr Pulmonol* 1987; 3: 153–60.

115 Sigurs N, Aljassim F, Kjellman B, et al. Asthma and allergy patterns over 18 years after severe RSV bronchiolitis in the first year of life. *Thorax* 2010; 65: 1045–52.

116 Stein RT, Sherrill D, Morgan WJ, et al. Respiratory syncytial virus in early life and risk of wheeze and allergy by age 13 years. *Lancet* 1999; 354: 341–45.

117 Fjaer O, Farstad T, Rod G, Ufert GK, Gulbrandson P, Nakstad B. Acute bronchiolitis in infancy as risk factor for wheezing and reduced pulmonary function by seven years in Akershus County, Norway. *BMC Pediatr* 2005; 5: 31.

118 Jeng MJ, Lee YS, Tsao FC, Yang CF, Soong WJ. A longitudinal study on early hospitalized airway infections and subsequent childhood asthma. *PloS One* 2014; 10: e0121906.

119 Carroll KN, Wu P, Gebretsadik T, et al. The severity-dependent relationship of infant bronchiolitis on the risk and morbidity of early childhood asthma. *J Allergy Clin Immunol* 2009; 123: 1055–61.e1.

120 Everard ML, Hind D, Ugonna K, et al. Saline in acute bronchiolitis: a multicenter, randomized, controlled trial. *PLoS Med* 2013; 10: e1001425.

121 Greening AP, Ind PW, Northfield M, Shaw G. Added salmeterol versus higher-dose corticosteroid in asthma patients with symptoms on existing inhaled corticosteroid. *Allen & Hanburys Limited UK Study Group. Lancet* 1994; 344: 219–24.

122 Pauwels RA, Lofdahl CG, Postma DS, et al. Effect of inhaled formoterol and budesonide on exacerbations of asthma. *Formoterol and Corticosteroids Establishing Therapy (FACET) International Study Group. N Engl J Med* 1997; 337: 1405–11.

123 Barnes PJ. Scientific rationale for using a single inhaler for asthma control. *Eur Respir J* 2007; 29: 587–95.

124 Giembycz MA, Kaur M, Leigh R, Newton R. A holy grail of asthma management: toward understanding how long-acting beta(2)-agonist-induced RGS2 expression is a genomic mechanism of bronchoprotection that is enhanced by glucocorticoids. *Br J Pharmacol* 2008; 153: 1090–104.

125 Kaur M, Chivers JE, Giembycz MA, Newton R. Long-acting beta-2-adrenoceptor agonists enhance the clinical efficacy of inhaled corticosteroids. *Lancet* 2004; 363: 587–95.

126 Holden NS, Bell MJ, Rider CF, et al. Beta 2-adrenoceptor agonist-induced RGS2 expression is a genomic mechanism of clinical efficacy of inhaled corticosteroids. *Thorax* 2004; 59: 219–24.

127 Stein RT, Sherrill D, Morgan WJ, et al. Respiratory syncytial virus in early life and risk of wheeze and allergy by age 13 years. *Lancet* 1999; 354: 341–45.